In addition, markers increasing from baseline in patients progressing through treatment include CXCL13, CCL17, and reduced clonal T-cell diversity, likely reflecting increasing tumor burden and activation of a Tfh axis previously associated with poor prognosis of lymphocyte-rich HL (16). The gene discussed is CCL17; the disease is neoplasm.